Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs.
Tsukamoto S, Sugi NH, Nishibata K, Nakazawa Y, Ito D, Fukushima S, Nakagawa T, Ichikawa K, Kato Y, Kakiuchi D, Goto A, Itoh-Yagi M, Aota T, Inoue S, Yamane Y, Murai N, Azuma H, Nagao S, Sasai K, Akagi T, Imai T, Matsui J, Matsushima T. Tsukamoto S, et al. Among authors: azuma h. Mol Cancer Ther. 2023 Jan 3;22(1):12-24. doi: 10.1158/1535-7163.MCT-21-0879. Mol Cancer Ther. 2023. PMID: 36279567
Discovery of a potent and selective Axl inhibitor in preclinical model.
Inoue S, Yamane Y, Tsukamoto S, Azuma H, Nagao S, Murai N, Nishibata K, Fukushima S, Ichikawa K, Nakagawa T, Hata Sugi N, Ito D, Kato Y, Goto A, Kakiuchi D, Ueno T, Matsui J, Matsushima T. Inoue S, et al. Among authors: azuma h. Bioorg Med Chem. 2021 Jun 1;39:116137. doi: 10.1016/j.bmc.2021.116137. Epub 2021 Apr 21. Bioorg Med Chem. 2021. PMID: 33930844
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S, Yamane Y, Tsukamoto S, Murai N, Azuma H, Nagao S, Nishibata K, Fukushima S, Ichikawa K, Nakagawa T, Hata Sugi N, Ito D, Kato Y, Goto A, Kakiuchi D, Ueno T, Matsui J, Matsushima T. Inoue S, et al. Among authors: azuma h. Bioorg Med Chem Lett. 2021 Sep 15;48:128247. doi: 10.1016/j.bmcl.2021.128247. Epub 2021 Jul 13. Bioorg Med Chem Lett. 2021. PMID: 34271070
Ten-Gram-Scale Total Synthesis of the Anticancer Drug Candidate E7130 to Supply Clinical Trials.
Kaburagi Y, Kira K, Yahata K, Iso K, Sato Y, Matsuura F, Ohashi I, Matsumoto Y, Isomura M, Sasaki T, Fukuyama T, Miyashita Y, Azuma H, Iida D, Ishida T, Itano W, Matsuda M, Matsukura M, Murai N, Nagao S, Seki M, Yamamoto A, Yamamoto Y, Yoneda N, Watanabe Y, Kamada A, Kayano A, Tagami K, Asano O, Owa T, Kishi Y. Kaburagi Y, et al. Among authors: azuma h. Org Lett. 2024 Apr 12;26(14):2837-2842. doi: 10.1021/acs.orglett.3c03663. Epub 2024 Jan 22. Org Lett. 2024. PMID: 38252895
Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease.
Ohkuro M, Kim JD, Kuboi Y, Hayashi Y, Mizukami H, Kobayashi-Kuramochi H, Muramoto K, Shirato M, Michikawa-Tanaka F, Moriya J, Kozaki T, Takase K, Chiba K, Agarwala KL, Kimura T, Kotake M, Kawahara T, Yoneda N, Hirota S, Azuma H, Ozasa-Komura N, Ohashi Y, Muratani M, Kimura K, Hishinuma I, Fukamizu A. Ohkuro M, et al. Among authors: azuma h. Nat Commun. 2018 May 17;9(1):1982. doi: 10.1038/s41467-018-04420-4. Nat Commun. 2018. PMID: 29773794 Free PMC article.
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S. Kaku K, et al. Among authors: azuma h. Diabetes Obes Metab. 2013 May;15(5):432-40. doi: 10.1111/dom.12047. Epub 2013 Jan 25. Diabetes Obes Metab. 2013. PMID: 23194084 Clinical Trial.
Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.
Yamada Y, Sato K, Sakamoto S, Tsujino T, Saito S, Nishimura K, Fukushima T, Nakamura K, Yoshikawa Y, Matsunaga T, Maenosono R, Kanesaka M, Arai T, Sazuka T, Imamura Y, Komura K, Mikami K, Nakamura K, Fukasawa S, Chiba K, Naya Y, Nagata M, Komaru A, Nakatsu H, Azuma H, Ichikawa T. Yamada Y, et al. Among authors: azuma h. Int J Clin Oncol. 2024 Dec 10. doi: 10.1007/s10147-024-02676-z. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39656401
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium.
Uchimoto T, Iwatsuki K, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Fujimoto S, Minami T, Yamamoto Y, Yamazaki S, Takai T, Sakamoto M, Nakajima Y, Nishimura K, Maenosono R, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yoshikawa Y, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Fujita K, Kimura T, Ohno Y, Shiroki R, Azuma H. Uchimoto T, et al. Among authors: azuma h. Int J Clin Oncol. 2024 Oct 28. doi: 10.1007/s10147-024-02649-2. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39467994
968 results